Home
>
US Stocks
>
Gritstone Oncology Inc

Gritstone Oncology Inc (GRTS)

$2.35

-0.15

(-6%)▲

Market is closed - opens 7 PM, 12 Jun 2023

Insights on Gritstone Oncology Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 12.00M → 2.44M (in $), with an average decrease of 79.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 5 quarters, -28.91M → -33.98M (in $), with an average decrease of 4.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 41.8% return, outperforming this stock by 37.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 137.5% return, outperforming this stock by 203.7%

Performance

  • $2.26
    $2.48
    $2.35
    downward going graph

    4.04%

    Downside

    Day's Volatility :9.07%

    Upside

    5.24%

    downward going graph
  • $1.64
    $5.85
    $2.35
    downward going graph

    30.21%

    Downside

    52 Weeks Volatility :71.97%

    Upside

    59.83%

    downward going graph

Returns

PeriodGritstone Oncology IncSector (Health Care)Index (Russel 2000)
3 Months
10.09%
5.1%
-0.2%
6 Months
-9.11%
-5.5%
-1.5%
1 Year
4.22%
3.9%
-1.7%
3 Years
-66.21%
27.0%
20.6%

Highlights

Market Capitalization
212.5M
Book Value
$1.6
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.53
Wall Street Target Price
8.6
Profit Margin
0.0%
Operating Margin TTM
-830.96%
Return On Assets TTM
-34.81%
Return On Equity TTM
-75.59%
Revenue TTM
15.2M
Revenue Per Share TTM
0.16
Quarterly Revenue Growth YOY
-66.0%
Gross Profit TTM
-91.5M
EBITDA
-119.5M
Diluted Eps TTM
-1.53
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.3
EPS Estimate Next Year
-1.32
EPS Estimate Current Quarter
-0.33
EPS Estimate Next Quarter
-0.33

Analyst Recommendation

Buy
    84%Buy
    7%Hold
    7%Sell
Based on 13 Wall street analysts offering stock ratings for Gritstone Oncology Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
9
Hold
1
1
1
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 265.96%

Current $2.35
Target $8.60

Technicals Summary

Sell

Neutral

Buy

Gritstone Oncology Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Gritstone Oncology Inc
Gritstone Oncology Inc
-11.51%
-9.11%
4.22%
-66.21%
-83.53%
Moderna, Inc.
Moderna, Inc.
-5.8%
-25.37%
-3.05%
105.16%
562.58%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.38%
0.57%
30.59%
23.1%
139.38%
Novo Nordisk A/s
Novo Nordisk A/s
-6.71%
21.75%
41.76%
137.45%
252.55%
Seagen, Inc.
Seagen, Inc.
-1.72%
49.08%
41.0%
25.43%
194.5%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.66%
6.21%
30.93%
21.64%
124.53%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Gritstone Oncology Inc
Gritstone Oncology Inc
NA
NA
NA
-1.3
-0.76
-0.35
0.0
1.6
Moderna, Inc.
Moderna, Inc.
10.82
10.82
0.0
-1.63
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.46
20.46
9.01
41.59
0.19
0.1
0.0
219.38
Novo Nordisk A/s
Novo Nordisk A/s
44.45
44.45
2.03
4.98
83.5
0.23
0.01
4.44
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.89
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
25.51
25.51
0.41
14.57
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Gritstone Oncology Inc
Gritstone Oncology Inc
Buy
$212.5M
-83.53%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$47.6B
562.58%
10.82
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$82.3B
139.38%
20.46
33.81%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$1.9T
252.55%
44.45
32.47%
Seagen, Inc.
Seagen, Inc.
Hold
$36.5B
194.5%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$85.1B
124.53%
25.51
35.4%

Institutional Holdings

  • Point72 Asset Management, L.P.

    8.64%

  • Redmile Group, LLC

    7.79%

  • Vanguard Group Inc

    4.12%

  • Versant Venture Management LLC

    4.01%

  • Balyasny Asset Management LLC

    2.31%

  • BlackRock Inc

    2.20%

Corporate Announcements

  • Gritstone Oncology Inc Earnings

    Gritstone Oncology Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

gritstone oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. the company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. gritstone oncology is headquartered in the san francisco bay area with certain key functions located in cambridge, ma. gritstone oncology launched in october 2015 with a series a financing of $102 million.

Organization
Gritstone Oncology Inc
Employees
233
CEO
Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.
Industry
Health Technology

Discover More

FAQs